Clinical trials: sponsored by Henan Cancer Hospital
Gastric Cancer, Adenocarcinoma of Esophagogastric Junction
TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma
This is a prospective one arm phase II clinical study to evaluate the efficacy and safety of TQB2450 (PD-L1 inhibitor), anlotinib combined with oxaliplatin and capecitabine in patients with unresectable locally advanced…
- Trial name
- NCT04891900
- Testing
- TQB2450/Anlotinib hydrochloride/Oxaliplatin/Capecitabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Henan Cancer Hospital
Relapsed/Refractory B-cell Lymphomas
L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma
L218CAR19 is a kind of chimeric antigen receptor T-cell immunotherapy targeting CD19 on B cells. The goal of this study is to determine the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity of…
- Trial name
- NCT06478381
- Testing
- L218CAR19
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Henan Cancer Hospital
Hepatocellular Carcinoma
Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib
Currently, it has been demonstrated that CDK4 is highly expressed in hepatocellular carcinoma patients and is significantly associated with poor prognosis in hepatocellular carcinoma patients.
- Trial name
- NCT06478927
- Testing
- Palbociclib capsules
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Henan Cancer Hospital
Metastatic Breast Cancer in the Brain
Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs
To evaluate the efficacy and safety of pyrotinib plus capecitabine in HER2-positive breast cancer patients with active brain metastases that have failed ADCs
- Trial name
- NCT06475443
- Testing
- pyrotinib plus capecitabine
- Volunteers
- 32 people
- Sponsor
- Henan Cancer Hospital
NSCLC
Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC
This study is an open-label Phase II clinical trial to evaluate the safety and efficacy of SHR-A1921 or SHR-A2009 in patients with advanced NSCLC who progressed after standard therapy.
- Trial name
- NCT06465238
- Testing
- SHR-A2009, SHR-A1921
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital
Non-Small Cell Lung Cancer NSCLC
Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)
It is a single-center, open-labeled, single-arm, non-randomized investigator-initiated trial evaluating the efficacy and safety of anti-Trop2 U-CAR-NK Cells Therapy combined with Chemotherapy for Relapsed/Refractory Non-Small…
- Trial name
- NCT06454890
- Testing
- Anti-Trop2 CAR-NK cell
- Volunteers
- 50 people
- Sponsor
- Henan Cancer Hospital
Chemotherapy, Immune Checkpoint Inhibitor
Toripalimab Plus FLOT in Locally Advanced Gastric Cancer
Neoadjuvant chemoimmunotherapy for locally advanced gastric and gastroesophageal junction (G/GEJ) cancer is currently under investigation.
- Conditions
- Chemotherapy, Immune Checkpoint Inhibitor, Locally Advanced Gastric Carcinoma
- Trial name
- NCT04891016
- Testing
- FLOT combined with toripalimab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Non-Small Cell Lung Cancer
An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small Cell Lung Cancer
This is a single-arm, open, multicenter exploratory clinical trial to observe and evaluate the efficacy and safety of Iruplinalkib Tablets in patients with ROS1 positive non-small cell lung cancer.
- Trial name
- NCT06436885
- Testing
- Iruplinalkib tablets
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Henan Cancer Hospital
Lymphoma, Mantle-Cell, Lymphoma, Non-Hodgkin
This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma
This is a phase II, open-label, multicentre study of Zanubrutinib-containing regimens in patients with newly diagnosed mantle cell lymphoma.
- Trial name
- NCT06427213
- Testing
- Zanubrutinib,Obinutuzumab, Zanubrutinib and R-BAC
- Volunteers
- 41 people
- Sponsor
- Henan Cancer Hospital
Extensive Small Cell Lung Cancer
A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer
Small cell lung cancer (SCLC) accounts for 15% of lung cancer cases and is an aggressive cancer characterized by rapid growth, early metastasis, and a poor prognosis.
- Trial name
- NCT06406673
- Testing
- Cadonilimab+EC/ET+RT, Cadonilimab+vorolanib
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Henan Cancer Hospital
Non-small Cell Lung Cancer
Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer
This study aims to enroll non-small cell lung cancer patients who have undergone at least two rounds of standard treatment for drug resistance/recurrence.
- Trial name
- NCT06406608
- Testing
- Chemotherapy and targeted-therapy guided by organoid drug sensitivity test
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Small Cell Lung Cancer
Patient-derived Organoid Drug Sensitivity Guided Treatment for Recurrent Small Cell Lung Cancer
This study plans to enroll 20 patients with recurrent small cell lung cancer. Patient-derived Organoid will be established, and drug sensitivity test will be conducted to intervene in the selection of clinical treatment plans.
- Trial name
- NCT06406660
- Testing
- Chemotherapy and targeted-therapy guided by organoid drug sensitivity test
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Lung Cancer, Nonsmall Cell, Esophageal Carcinoma
Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
To explore the dose and safety of thalidomide for the prevention and treatment of camrelizumab-induced reactive cutaneous capillary endothelial proliferation (RCCEP)
- Trial name
- NCT06231680
- Testing
- Camrelizumab, Thalidomide 50mg, Thalidomide 100mg
- Where
- 2 sites in China
- Volunteers
- 132 people
- Sponsor
- Henan Cancer Hospital
Non-Squamous Non-Small Cell Lung Cancer
Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure
The purpose of this study is to evaluate the efficacy and safety of Serplulimab Plus Bevacizumab and chemotherapy in TKI-resistant EGFR-mutated non-squamous NSCLC Chinese patients.
- Trial name
- NCT06334757
- Testing
- Serplulimab, Bevacizumab Biosimilar HLX04, Pemetrexed
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Henan Cancer Hospital
Metastatic Colon Cancer
PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer
Evaluate the efficacy and safety of PD1 monoclonal antibody combined with mFOLFOX6 neoadjuvant therapy for advanced resectable metastatic colon cancer with enriched pro-inflammatory pan macrophage subpopulations
- Trial name
- NCT06335147
- Testing
- Serplulimab, mFOLFOX6
- Volunteers
- 23 people
- Sponsor
- Henan Cancer Hospital
Colorectal Cancer
TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer
This study is a randomized, controlled, open-label, multicentre clinical study. This study is designed to evaluate the efficacy and safety of TAS-102 combined with bevacizumab as second-line maintenance therapy versus standard…
- Trial name
- NCT06293014
- Testing
- TAS-102+bevacizumab, Standard chemotherapy+bevacizumab
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Henan Cancer Hospital
Stage IV Breast Cancer
Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Breast Cancer Patients
The purpose of this study is to compare the effect of primary resection combined with systemic therapy and pure systemic therapy on the overall survival of patients with stage Ⅳ breast cancer.
- Trial name
- NCT04199520
- Testing
- surgery combined with systemic therapy, systemic therapy
- Where
- China
- Sponsor
- Henan Cancer Hospital
HCC
Tace With Icaritin in First-line Treatment of Middle and Advanced HCC in Child Grade B Patients
Icaritin is a drug that has been approved by the National Medical Products Administration (NMPA) based on a multicenter, randomized, double-blind, parallel-controlled Phase III clinical trial - SNG1705 ICR-1.
- Trial name
- NCT06285149
- Testing
- Icaritin
- Volunteers
- 80 people
- Sponsor
- Henan Cancer Hospital
Gastric Cancer
SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma
The aim of this study is to observe the efficacy and safety of immume checkpoint inhibitor PD-1 SHR1210 combined with Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of locally advanced resectable gastric and…
- Trial name
- NCT03950271
- Testing
- SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer, HER2-positive Breast Cancer
A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer
In 2020, the incidence of breast cancer surpassed that of lung cancer for the first time, becoming the number one cancer in the world. HER2 is an important prognostic indicator and therapeutic target for breast cancer.
- Trial name
- NCT05474690
- Testing
- Docetaxel + Carboplatin + Trastuzumab + Pertuzumab, (Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab)
- Where
- China
- Sponsor
- Henan Cancer Hospital